Fulvestrant 500mg in Patients With Advanced Breast Cancer

Fudan University500 enrolled

Overview

A multicenter, prospective study real-world to evaluate the safety profile and effectiveness in Chinese patients who received Fulvestrant 500mg as first-line endocrine treatment for Advanced breast cancer

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Metastatic Breast Cancer

Interventions

FulvestrantDRUG

500 mg on days 0, 14, and 28, and every 28 days thereafter

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Chinese women with estrogen receptor positive, locally advanced or metastatic breast cancer who has already received Fulvestant 500mg treatment as determined by treating physician. Ovarian suppression in premenopausal women is permitted, including ovarian ablation and LHRHa. 2. Histologically confirmed positive oestrogen receptor status (ER positive) of primary breast cancer or metastatic tumour tissue, according to the local laboratory parameters. 3. Prior endocrine therapy for advanced disease was not permitted. 4. The prescription of the Fulvestant is clearly separated from the decision to include the subject in the NIS, and is part of normal medical practice. The recruitment of the patient to the study should be within 1 month of the first Fulvestant injection. 5. Provision of subject informed consent. Exclusion Criteria: 1. If participating in any controlled clinical trial, the subject cannot take part in this study. 2. HER2 overexpression or gene amplification, ie, immunohistochemistry (IHC) 3+ or fluorescence in situ hybridisation (FISH)+, where appropriate. 3. Pervious regimen of endocrine therapy for advanced disease. 4. More than one regimen of chemotherapy for advanced disease. 5. Pregnancy and lactation. 6. Severe hepatic impairment.

Locations (1)

Fudan University Cancer Hospital

Shanghai, China

Outcomes

Primary Outcomes

Incidence, nature and severity of all Adverse Events assessed by CTCAE V4.0

Time frame: From date of randomization until the date of date of death from any cause or last visit, assessed up to 100 months.

Secondary Outcomes

ORR

Objective Response Rate

Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.

CBR

Clinical Benefit Rate

Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.

PFS

Progression Free Survival

Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.

Overall Survival

Time frame: From date of randomization until the date of date of death from any cause or last visit, assessed up to 100 months.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.